Szemészet, 2021 (158. évfolyam, 1-4. szám)

2021-03-01 / 1. szám

Irodalom

1. Al-Dhibi

H,

Abouammoh M, Al-Harthi

E,

Al-Gaeed

A, Larsson J, Abboud E, Chaudhry I. Macular hole in Behcet’s disease. Indian J Ophthalmol 2011; 59: 359-562.

2. Chan

A, Duker

JS,

Ko TH, Fujimoto JG, Schuman JS. Normal Macular Thickness Measurements in Healthy Eyes Using Stratus Optical Coherence Tomography. Arch Ophthalmol 2006; 124: 193-198.

3. Coscas

F, Sellam

A,

Glacet-Bernard A, Jung C,

Goudot

M, Miere

A,

Souied EH. Normative Data for Vascular Density in Superficial and Deep Capillary Plexuses of Healthy Adults Assessed by Optical Coherence Tomography Angiography. Invest Ophthalmol Vis Sei

2016;

57: 211-23.

4. Duker

JS,

Kaiser PK, Binder S, de Smet MD,Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013; 120: 2611-2619.

5. International

Study Group for Behget's Disease: Criteria for diagnosis of Behget's disease. Lancet 1990; 335:1078-1080.

6. Khairallah

M,

Abroug

N, Khochtali S, Mahmoud A, Jelliti B, Coscas G, Lupidi M,

Kahloun

R, Ben Yahia

S.

Optical coherence tomography angiography in patients with Behget uveitis. Retina n2017; 37:1678-1691.

7. Kitaichi

N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol 2007; 91: 1579-82.

8. Kurokawa

MS, Suzuki N. Behget’s Disease. Clin Exp Med 2004; 3:10-20.

9. Kusuhara

S, Teraoka Escano MF, Fujii S, Nakanishi Y, Tamura Y, Nagai A, Yamamoto H, Tsukahara Y, Negi A. Prediction of postoperative visual outcome based on hole configuration by optical coherence tomography in eyes with idiopathic macular holes. Am J Ophthalmol 2004; 138: 709-716.

10. Sakane

T, Takeno M, Suzuki N, Inaba G. Behget’s disease. N Engl J Med

1999; 341: 1284-1291.

11. Saleh

Z, Arayssi T. Update on the therapy of Behget disease. Ther Adv Chronic Dis 2014; 5:112-134.

12. Sullu

Y,

Alotaiby

H, Beden

U,

Erkan D. Pars plana vitrectomy for ocular complications of Behget's disease. Ophthalmic Surg Lasers Imaging 2005; 36: 292-297.

13. Tugal-Tutkun

I, Onal S,

Altan-Yaycioglu

R, Huseyin Altunbas

H,

Urgancioglu M. Uveitis in Behget disease:an analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-80.

14. Ugar

0,

Atalay

E,

Özyazgan

Y, Özkök

A,

Yildirim

Y. An exceptional

case of full- thickness macular hole closure in a patient with Behget disease. Ocul Immunol Inflamm 2014; 22: 79-81.

15. Verity

DH,

Marr

JE,

Ohno

S, Wallace GR, Stanford MR. Behget’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999; 54: 213-220.

16. Wilczyski

T, Heinke

A,

Niedzielska-Krycia A, Jorg 0, Michalska-Mafecka K. Optical coherence tomography angiography features in patients with idiopathic full-thickness macular hole, before and after surgical treatment. Clin Interv Aging 2019; 14: 505-514.

17. Wu

TT,

Hong

MC.

Pars

plana vitrectomy with internal limiting membrane removal for a macular hole associated with Behget’s disease. Eye (Lond) 2009; 23: 1606-1607.

18. Yurdakul

S,

Yazici

Y, et al. Epidemiology of Behcet's syndrome and regional differences in disease expression. Behcet’s syndrome. 1th ed., New York: Springer; 2010. p. 35-52.

19. Zeidan

MJ, Saadoun D, Garrido M,

Klatzmann

D, Six A, Cacoub P. Behget’s disease physiopathology: a contemporary review. Auto

Immun High

lights 2016; 7:4.

De Rynkiewicz Judit, Jahn Ferenc Dél-pesti

Kórház és Rendelőintézet, Szemészet 1204 Budapest, Köves út 1. E-mail: rynkijudit@gmail.com

TROPHOSAN Visiobalance

Időskori makuladegenerációs betegek diétás ellátására

lüfflBS

Speciális - gyógyászati célra szánt - élelmiszer

TROPHOSAN Visiobalance kapható havi ill. 3

havi kiszerelésben.

Napi 2x2, azaz a 4 kapszula összetétele összehasonlítva az AREDS 2 formulával:

/ C-vitamin 500 mg / E-vitamin 400 IU / cink (oxid) 80 mg

/ réz (cifrát) 2 mg / zeaxanthin 2 mg

/ lutein

10

mg

AREDS 1 és 2 tanulmány szerinti formulával.

Speciális - gyógyászati Célra a®

’’"®®

Idő* makulad^ betegekéire«**

Forgalmazó: Dr. Kocsis & Hoffmann

Pharma Kft.

1024 Budapest, Retek utca 32.; Tel.: +361 438 0257; e-mail: drkh@drkh.hu

;

Gyártó: Protina Pharm. GmbH 85737 Ismaning,

Adalperostrasse

37. Németország

www.trophosan.hu

Kapható a gyógyszertárakban

i o b

a

I

a

/ X

• 36 j